文献速递糖尿病肥胖与代谢综合征

评估二甲双胍靶点AMPK激活对英国生物银行中心血管疾病和癌症风险的影响:一项孟德尔随机化研究

Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study.
PubMed 文献 · Diabetologia · 2020-08-04

本研究采用孟德尔随机化设计,以AMPK变异作为工具变量,在英国生物银行391199名白人英国裔参与者中评估AMPK通路依赖的二甲双胍效应。遗传预测的AMPK介导HbA1c降低与2型糖尿病风险降低61%、冠状动脉疾病风险降低53%、总体癌症风险降低44%相关。作者认为该遗传证据提示二甲双胍激活AMPK可能预防心血管疾病和癌症,但需随机对照试验证实。

要点

  • AMPK变异预测的HbA1c降低与2型糖尿病风险降低相关(OR 0.39;95%CI 0.20,0.78)。
  • AMPK变异预测的HbA1c降低与冠状动脉疾病风险降低相关(OR 0.47;95%CI 0.26,0.84)。
  • AMPK变异预测的HbA1c降低与总体癌症风险降低相关(OR 0.56;95%CI 0.36,0.85)。

核心结论

  • 本研究提供了一些遗传证据,提示二甲双胍激活AMPK可能预防心血管疾病和癌症,但需随机对照试验证实。

研究设计与样本

  • 孟德尔随机化设计,使用二甲双胍的药理靶点AMPK推断二甲双胍的AMPK通路依赖效应。
  • 研究对象为英国生物银行中白人英国裔参与者,共纳入391199人(平均年龄56.9岁;女性占54.1%)。

主要发现

  • 共包含26690例2型糖尿病、38098例冠状动脉疾病和80941例总体癌症病例。
  • AMPK变异工具变量预测的HbA1c(%)降低与2型糖尿病风险降低61%相关(OR 0.39;95%CI 0.20,0.78;p=7.69×10⁻³)。
  • AMPK变异工具变量预测的HbA1c(%)降低与冠状动脉疾病风险降低53%相关(OR 0.47;95%CI 0.26,0.84;p=0.01)。
  • AMPK变异工具变量预测的HbA1c(%)降低与总体癌症风险降低44%相关(OR 0.56;95%CI 0.36,0.85;p=7.23×10⁻³)。
  • 使用AMPK评分中位数或四分位数时结果相似,呈剂量反应效应(2型糖尿病趋势p=4.18×10⁻³,冠状动脉疾病趋势p=4.37×10⁻³,总体癌症趋势p=4.04×10⁻³)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出该研究结果需随机对照试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Whether metformin reduces cardiovascular or cancer risk is unclear owing to concerns over immortal time bias and confounding in observational studies. This study evaluated the effect of AMP-activated protein kinase (AMPK), the target of metformin, on risk of cardiovascular disease and cancer. METHODS: This is a Mendelian randomisation design, using AMPK, the pharmacological target of metformin, to infer the AMPK pathway-dependent effects of metformin on risk of cardiovascular disease and cancer in participants of white British ancestry in the UK Biobank. RESULTS: A total of 391,199 participants were included (mean age 56.9 years; 54.1% women), including 26,690 cases of type 2 diabetes, 38,098 cases of coronary artery disease and 80,941 cases of overall cancer. Genetically predicted reduction in HbA1c (%) instrumented by AMPK variants was associated with a 61% reduction in risk of type 2 diabetes (OR 0.39; 95% CI 0.20, 0.78; p = 7.69 × 10-3), a 53% decrease in the risk of coronary artery disease (OR 0.47; 95% CI 0.26, 0.84; p = 0.01) and a 44% decrease in the risk of overall cancer (OR 0.56; 95% CI 0.36, 0.85; p = 7.23 × 10-3). Results were similar using median or quartiles of AMPK score, with dose-response effects (p for trend = 4.18 × 10-3 for type 2 diabetes, 4.37 × 10-3 for coronary artery disease and 4.04 × 10-3 for overall cancer). CONCLUSIONS/INTERPRETATION: This study provides some genetic evidence that AMPK activation by metformin may protect against cardiovascular disease and cancer, which needs to be confirmed by randomised controlled trials.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Luo S, Schooling CM, Wong ICK, et al. Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study. Diabetologia. 2020. PMID: 32748028. doi:10.1007/s00125-020-05243-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。